ES2792069T3 - Formulación de liberación controlada de hidrocortisona - Google Patents

Formulación de liberación controlada de hidrocortisona Download PDF

Info

Publication number
ES2792069T3
ES2792069T3 ES13709499T ES13709499T ES2792069T3 ES 2792069 T3 ES2792069 T3 ES 2792069T3 ES 13709499 T ES13709499 T ES 13709499T ES 13709499 T ES13709499 T ES 13709499T ES 2792069 T3 ES2792069 T3 ES 2792069T3
Authority
ES
Spain
Prior art keywords
hydrocortisone
composition
composition according
release
delayed release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13709499T
Other languages
English (en)
Spanish (es)
Inventor
Hiep Huatan
Richard Ross
Martin Whitaker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immedica UK Ltd
Original Assignee
Diurnal Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Diurnal Ltd filed Critical Diurnal Ltd
Application granted granted Critical
Publication of ES2792069T3 publication Critical patent/ES2792069T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/07—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of capsules or similar small containers for oral use
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Addiction (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES13709499T 2012-02-13 2013-02-12 Formulación de liberación controlada de hidrocortisona Active ES2792069T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB1202433.7A GB201202433D0 (en) 2012-02-13 2012-02-13 Controlled drug release
US201261599704P 2012-02-16 2012-02-16
US201261600958P 2012-02-20 2012-02-20
PCT/GB2013/050311 WO2013121184A1 (en) 2012-02-13 2013-02-12 Hydrocortisone controlled release formulation

Publications (1)

Publication Number Publication Date
ES2792069T3 true ES2792069T3 (es) 2020-11-06

Family

ID=45930017

Family Applications (1)

Application Number Title Priority Date Filing Date
ES13709499T Active ES2792069T3 (es) 2012-02-13 2013-02-12 Formulación de liberación controlada de hidrocortisona

Country Status (29)

Country Link
US (2) US9750704B2 (enExample)
EP (1) EP2814469B1 (enExample)
JP (1) JP6293678B2 (enExample)
KR (1) KR102023559B1 (enExample)
CN (2) CN110141557A (enExample)
AU (1) AU2013220139B2 (enExample)
BR (1) BR112014020008B1 (enExample)
CA (1) CA2864031C (enExample)
CY (1) CY1123202T1 (enExample)
DK (1) DK2814469T3 (enExample)
ES (1) ES2792069T3 (enExample)
GB (2) GB201202433D0 (enExample)
HK (1) HK1203824A1 (enExample)
HR (1) HRP20200780T1 (enExample)
HU (1) HUE048904T2 (enExample)
IL (2) IL234061B (enExample)
IN (1) IN2014DN06808A (enExample)
LT (1) LT2814469T (enExample)
ME (1) ME03742B (enExample)
MX (1) MX361407B (enExample)
NZ (2) NZ715616A (enExample)
PL (1) PL2814469T3 (enExample)
PT (1) PT2814469T (enExample)
RS (1) RS60346B1 (enExample)
RU (1) RU2619869C2 (enExample)
SI (1) SI2814469T1 (enExample)
SM (1) SMT202000286T1 (enExample)
WO (1) WO2013121184A1 (enExample)
ZA (1) ZA201508728B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201202433D0 (en) 2012-02-13 2012-03-28 Diurnal Ltd Controlled drug release
US20160367755A1 (en) * 2015-06-01 2016-12-22 Massachusetts Institute Of Technology System and method for neuroendocrine control
FR3057775B1 (fr) * 2016-10-26 2018-11-02 Crossject Solution pharmaceutique d’hydrocortisone pour dispositif d’injection
KR101982287B1 (ko) * 2019-01-04 2019-05-24 (주)청아굿푸드 천연 추출물 함유 서방성 제제 및 그 제조방법
WO2022152863A1 (en) 2021-01-15 2022-07-21 Galventa Gmbh Pulsatile release caffeine formulation
MX2023012437A (es) * 2021-04-22 2023-11-07 Civi Biopharma Inc Administracion oral de oligonucleotidos.
US11904046B1 (en) 2022-11-14 2024-02-20 Eton Pharmaceuticals, Inc. Hydrocortisone oral liquid formulations
WO2025240605A1 (en) * 2024-05-15 2025-11-20 Neurocrine Biosciences, Inc. Combination treatment

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4552872A (en) 1983-06-21 1985-11-12 The Procter & Gamble Company Penetrating topical pharmaceutical compositions containing corticosteroids
JPS6013711A (ja) * 1983-06-21 1985-01-24 ザ、プロクタ−、エンド、ギヤンブル、カンパニ− コルチコステロイドを含有する浸透局所製薬組成物
GB2292079B (en) * 1994-08-12 1998-07-15 Flexpharm Ltd Coated prednisolone preparation for the treatment of inflamatory bowel disease
IL116674A (en) * 1995-01-09 2003-05-29 Mendell Co Inc Edward Microcrystalline cellulose-based excipient having improved compressibility, pharmaceutical compositions containing the same and methods for the preparation of said excipient and of solid dosage form thereof
US5686106A (en) 1995-05-17 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form for colonic delivery
DK0876142T3 (da) 1996-01-16 2001-11-19 Advanced Polymer Systems Inc Topisk tilførsel af lægemidler til den nedre mavetarmkanal
DE19718012C1 (de) 1997-04-29 1998-10-08 Jenapharm Gmbh Verfahren zur Herstellung peroral anwendbarer fester Arzneiformen mit gesteuerter Wirkstoffabgabe
US6066339A (en) * 1997-10-17 2000-05-23 Elan Corporation, Plc Oral morphine multiparticulate formulation
EP1315481B1 (de) 2000-08-29 2006-12-06 Mepha AG Arzneimittel zur behandlung von darmerkrankungen
KR20040047747A (ko) * 2001-03-13 2004-06-05 펜웨스트 파머슈티칼즈 컴파니 변시치료 제형
IL160217A0 (en) 2001-08-06 2004-07-25 Euro Celtique Sa Compositions and methods to prevent abuse of opioids
GB0119848D0 (en) 2001-08-15 2001-10-10 Univ Sheffield Delayed and sustained drug release
AU2002226955B2 (en) 2001-11-23 2006-04-27 Allergan Pharmaceuticals International Limited Pharmaceutical dosage form with multiple coatings
DE602004028497D1 (de) 2003-09-15 2010-09-16 Nycomed Gmbh Verwendung von ciclesonid zur behandlung von entzündlichen darmerkrankungen
GB0400031D0 (en) * 2004-01-03 2004-02-04 Univ Sheffield Depression treatment
SE0401031D0 (sv) * 2004-04-22 2004-04-22 Duocort Ab A new glucocorticoid replacement therapy
PT2049123E (pt) 2006-08-03 2013-03-06 Horizon Pharma Ag Tratamento de doença reumatóide com glucocorticóide de libertação retardada
WO2008059062A1 (en) 2006-11-17 2008-05-22 Da Volterra Colonic delivery using zn/pectin beads with a eudragit coating.
WO2008117814A1 (ja) 2007-03-26 2008-10-02 Teikoku Seiyaku Co., Ltd. 大腸送達用経口製剤
CA2709561A1 (en) * 2007-12-17 2009-06-25 Combinatorx, Incorporated Therapeutic regimens for the treatment of immunoinflammatory disorders
GB0817120D0 (en) * 2008-09-19 2008-10-29 Diurnal Ltd Treatment of adrenal insufficiency
NZ582836A (en) 2009-01-30 2011-06-30 Nitec Pharma Ag Delayed-release glucocorticoid treatment of rheumatoid arthritis by improving signs and symptoms, showing major or complete clinical response and by preventing from joint damage
WO2010113177A2 (en) * 2009-03-31 2010-10-07 Reliance Life Sciences Pvt. Ltd. Oral insulin delivery systems for controlling diabetes
NZ595428A (en) * 2009-04-07 2013-04-26 Duocourt Pharma Ab Improved glucocorticoid therapy
KR20120110098A (ko) 2009-11-16 2012-10-09 에보니크 룀 게엠베하 고형 (메트)아크릴레이트 공중합체를 분산제에 의해 분산된 형태로 전환시키는 방법
IT1405012B1 (it) * 2010-08-06 2013-12-16 Sofar Spa Composizioni di beclometasone dipropionato in microsfere gastroresistenti a rilascio modificato e processo per il loro ottenimento
GB201202433D0 (en) 2012-02-13 2012-03-28 Diurnal Ltd Controlled drug release

Also Published As

Publication number Publication date
US20140370113A1 (en) 2014-12-18
CN104105481A (zh) 2014-10-15
CA2864031C (en) 2019-11-12
AU2013220139B2 (en) 2017-08-31
SMT202000286T1 (it) 2020-07-08
IN2014DN06808A (enExample) 2015-05-22
ZA201508728B (en) 2017-09-27
AU2013220139A1 (en) 2014-08-07
SI2814469T1 (sl) 2020-07-31
MX2014009716A (es) 2015-01-14
JP6293678B2 (ja) 2018-03-14
US10166194B2 (en) 2019-01-01
GB2502402A (en) 2013-11-27
CY1123202T1 (el) 2021-10-29
BR112014020008B1 (pt) 2022-05-24
IL245546A0 (en) 2016-06-30
GB2502402B (en) 2014-11-12
PT2814469T (pt) 2020-05-22
RU2014130866A (ru) 2016-04-10
PL2814469T3 (pl) 2020-07-13
JP2015506972A (ja) 2015-03-05
ME03742B (me) 2021-04-20
LT2814469T (lt) 2020-05-25
NZ627468A (en) 2016-02-26
BR112014020008A8 (pt) 2018-01-23
US20170296475A1 (en) 2017-10-19
HUE048904T2 (hu) 2020-08-28
NZ715616A (en) 2017-03-31
DK2814469T3 (da) 2020-05-04
US9750704B2 (en) 2017-09-05
GB201302406D0 (en) 2013-03-27
CN110141557A (zh) 2019-08-20
RU2619869C2 (ru) 2017-05-18
EP2814469A1 (en) 2014-12-24
MX361407B (es) 2018-12-04
CA2864031A1 (en) 2013-08-22
HK1203824A1 (en) 2015-11-06
IL234061A0 (en) 2014-09-30
KR102023559B1 (ko) 2019-09-23
WO2013121184A1 (en) 2013-08-22
RS60346B1 (sr) 2020-07-31
HRP20200780T1 (hr) 2020-10-02
EP2814469B1 (en) 2020-04-08
GB201202433D0 (en) 2012-03-28
IL234061B (en) 2018-03-29
KR20140121478A (ko) 2014-10-15

Similar Documents

Publication Publication Date Title
US10166194B2 (en) Hydrocortisone controlled release formulation
ES2550035T3 (es) Sistemas de administración de fármacos que comprenden un agente de bloqueo selectivo de la serotonina 5-HT3 débilmente básico y ácidos orgánicos
ES2568746T3 (es) Sistemas de liberación pulsátil controlada
ES2459018T3 (es) Formulaciones de efectores de la unión estrecha
US10155006B2 (en) Combination therapies and methods of use thereof for treating cancer
RU2504362C2 (ru) Системы доставки лекарственных веществ, включающие в себя слабоосновные лекарственные вещества и органические кислоты
ES2922749T3 (es) Composiciones de sabor agradable que incluyen fenilbutirato de sodio y sus usos
ES2204517T3 (es) Composiciones de capsula farmaceutica que contienen loratadina y pseudoefedrina.
KR102466192B1 (ko) 간세포성 암종의 치료를 위한 조합 요법
ES2813382T3 (es) Composición que comprende hidrocortisona
JP2022549137A (ja) イブジラスト経口製剤およびその使用方法
US12472160B2 (en) Modified-release tiopronin compositions, kits and methods for treating cystinuria and related disorders
EP3993809B1 (en) System for enhancing therapeutic compliance of the anti-cancer compound e7766
WO2019023346A1 (en) MODIFIED RELEASE BUCILLAMINE COMPOSITIONS, KITS AND METHODS FOR TREATING CYSTINURIA, ARTHRITIS, GOUTTE AND OTHER RELATED DISORDERS
JP2007531727A (ja) Ｇａｂａｂ受容体アゴニストを含有する即時放出特性および／または制御放出特性を有する薬学的剤形
JP2003512311A (ja) Ｃｎｓ介在性障害を治療するための持続放出製剤
GB2510754A (en) Delayed release hydrocortisone composition
ES2804348T3 (es) Formulaciones de liberación controlada de levodopa y usos de las mismas
MX2008009616A (en) Drug delivery systems comprising weakly basic selective serotonin 5-ht3 blocking agent and organic acids